2023
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency
Stecklein S, Barlow W, Pusztai L, Timms K, Kennedy R, Logan G, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. JCO Precision Oncology 2023, 7: e2300197. PMID: 37972336, PMCID: PMC10681491, DOI: 10.1200/po.23.00197.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHomologous recombination deficiencyBreast cancerAdjuvant anthracycline-based chemotherapyTherapeutic vulnerabilitiesRecombination deficiencyDistinct therapeutic vulnerabilitiesAnthracycline-based chemotherapyImmune response signaturesDNA-damaging therapiesFavorable prognosisIntermediate prognosisWorse prognosisImmunologic microenvironmentImmune responseChemoresistant tumorsPrognostic classificationHeterogeneous diseasePrognosisHeterogeneous groupDistinct subgroupsTumorsCancerResponse signatureSimultaneous assessment
2004
Improving patient care through molecular diagnostics
Perez EA, Pusztai L, van De Vijver M. Improving patient care through molecular diagnostics. Seminars In Oncology 2004, 31: 14-20. PMID: 15490370, DOI: 10.1053/j.seminoncol.2004.07.017.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsDihydrouracil Dehydrogenase (NADP)Gene Expression ProfilingGenes, erbB-2HumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesOligonucleotide Array Sequence AnalysisProteomicsReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionThymidine PhosphorylaseConceptsLymph node statusPresence of metastasesSpecific tumor subtypesSingle tumor markerAdverse eventsMolecular diagnosticsNode statusSpecific therapyBreast cancerEstrogen receptorHistologic appearanceTumor gradingTumor markersTumor subtypesPatient careDiagnostic testsInitial evaluationParticular molecular defectsPatientsTherapyCancerParticular treatmentTreatmentSimultaneous assessmentDiagnostic techniques